A Double-blind, Randomized, Placebo-controlled, Sequential, Single, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Parameters of Subcutaneous Injections of GZR18 in Healthy Subjects
Latest Information Update: 27 Mar 2023
Price :
$35 *
At a glance
- Drugs GZR 18 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Gan&Lee Pharmaceuticals
- 22 Mar 2023 Status changed from recruiting to completed.
- 21 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Apr 2023.
- 21 Dec 2022 Planned primary completion date changed from 1 Nov 2022 to 1 Mar 2023.